IKT
- Inhibikase Therapeutics, Inc.
()
Overview
Company Summary
Inhibikase Therapeutics, Inc. (IKT) is a biopharmaceutical company that specializes in developing novel treatments for neurodegenerative diseases. The company focuses primarily on discovering therapies for diseases caused by abnormal protein accumulation in the brain, such as Parkinson's disease and Alzheimer's disease.
IKT's approach revolves around targeting specific enzymes that are responsible for the accumulation of toxic proteins. These enzymes, known as kinases, play a critical role in the progression of neurodegenerative disorders. By inhibiting these kinases, IKT aims to slow down or halt the disease progression, thereby providing potential treatments or even cures.
The company combines drug discovery technology, preclinical research, and clinical development strategies to find and develop small molecule drugs that can selectively inhibit these kinases. By doing so, IKT intends to restore normal cellular function and prevent the accumulation and spread of toxic proteins in the brain.
In addition to its primary focus on neurodegenerative diseases, IKT also explores the potential of its technology platform in other disease areas, including cancer and infectious diseases. The company's ultimate goal is to address significant unmet medical needs and improve the lives of patients facing these debilitating conditions.